- Title
- Precision medicine : an optimal approach to patient care in renal cell carcinoma
- Creator
- Sharma, Revati; Kannourakis, George; Prithviraj, Prashanth; Ahmed, Nuzhat
- Date
- 2022
- Type
- Text; Journal article; Review
- Identifier
- http://researchonline.federation.edu.au/vital/access/HandleResolver/1959.17/189490
- Identifier
- vital:17462
- Identifier
-
https://doi.org/10.3389/fmed.2022.766869
- Identifier
- ISSN:2296-858X (ISSN)
- Abstract
- Renal cell cancer (RCC) is a heterogeneous tumor that shows both intra- and inter-heterogeneity. Heterogeneity is displayed not only in different patients but also among RCC cells in the same tumor, which makes treatment difficult because of varying degrees of responses generated in RCC heterogeneous tumor cells even with targeted treatment. In that context, precision medicine (PM), in terms of individualized treatment catered for a specific patient or groups of patients, can shift the paradigm of treatment in the clinical management of RCC. Recent progress in the biochemical, molecular, and histological characteristics of RCC has thrown light on many deregulated pathways involved in the pathogenesis of RCC. As PM-based therapies are rapidly evolving and few are already in current clinical practice in oncology, one can expect that PM will expand its way toward the robust treatment of patients with RCC. This article provides a comprehensive background on recent strategies and breakthroughs of PM in oncology and provides an overview of the potential applicability of PM in RCC. The article also highlights the drawbacks of PM and provides a holistic approach that goes beyond the involvement of clinicians and encompasses appropriate legislative and administrative care imparted by the healthcare system and insurance providers. It is anticipated that combined efforts from all sectors involved will make PM accessible to RCC and other patients with cancer, making a tremendous positive leap on individualized treatment strategies. This will subsequently enhance the quality of life of patients. Copyright © 2022 Sharma, Kannourakis, Prithviraj and Ahmed.
- Publisher
- Frontiers Media S.A.
- Relation
- Frontiers in Medicine Vol. 9, no. (2022), p.
- Rights
- All metadata describing materials held in, or linked to, the repository is freely available under a CC0 licence
- Rights
- https://creativecommons.org/licenses/by/4.0/
- Rights
- Copyright © 2022 Sharma, Kannourakis, Prithviraj and Ahmed.
- Rights
- Open Access
- Subject
- 32 Biomedical and clinical sciences; 42 Health Sciences; Artificial intelligence; Gut microbiome; Nanomedicine; Precision medicine; Renal cell carcinoma
- Full Text
- Reviewed
- Funder
- This study was supported by John Turner Cancer Research Funds to Fiona Elsey Cancer Research Institute, Ballarat, Australia. RS is a recipient of a John Turner Cancer Research PhD scholarship, Fiona Elsey Cancer Research Institute, and Federation University Australia, Ballarat, Australia. This study was made possible through funds from John Turner Cancer Research Funds and the Victorian State Government Operational Infrastructure Support to Hudson Institute of Medical Research.
- Hits: 338
- Visitors: 362
- Downloads: 45
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Published version | 1 MB | Adobe Acrobat PDF | View Details Download |